- Home
- UBFO vs CRDF Comparison
UBFO vs CRDF Comparison
Compare UBFO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBFO | CRDF |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.8M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UBFO | CRDF |
|---|---|---|
| Price | $10.05 | $2.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.63 |
| AVG Volume (30 Days) | 22.0K | ★ 730.8K |
| Earning Date | 10-16-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $45,922,000.00 | $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.32 | $1.90 |
| 52 Week High | $10.49 | $5.64 |
Technical Indicators
Market Signals| Indicator | UBFO | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 64.95 | 50.06 |
| Support Level | $9.83 | $2.03 |
| Resistance Level | $10.10 | $2.37 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 90.67 | 55.32 |
Price Performance
Historical ComparisonAbout UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.